CMS Manual System	Department of Health & Human Services (DHHS)
Pub 100-20 One-Time Notification	Centers for Medicare & Medicaid Services (CMS)
Transmittal 10670	Date: March 12, 2021
	Change Request 12016

Transmittal 10552, dated January 5, 2021, is being rescinded and replaced by Transmittal 10670, dated, March 12, 2021 to update the effective date from date of service to receipt date. All other information remains the same.

**SUBJECT: Modification to Existing Common Working File (CWF) Edits for Osteoporosis Drug Codes Billable on Home Health Claims** 

**I. SUMMARY OF CHANGES:** This change request adds instructions to modify the existing CWF edits '5384' and '7283' for billing and paying additional codes for osteoporosis drugs under the home health benefit.

### EFFECTIVE DATE: January 1, 2021 - For claims received on or after this date

\*Unless otherwise specified, the effective date is the date of service.

**IMPLEMENTATION DATE: July 6, 2021** 

Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

**II. CHANGES IN MANUAL INSTRUCTIONS:** (N/A if manual is not updated) R=REVISED, N=NEW, D=DELETED-*Only One Per Row*.

R/N/D	CHAPTER / SECTION / SUBSECTION / TITLE	
N/A		

### III. FUNDING:

### For Medicare Administrative Contractors (MACs):

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

### IV. ATTACHMENTS:

**One Time Notification** 

# **Attachment - One-Time Notification**

Transmittal 10552, dated January 5, 2021, is being rescinded and replaced by Transmittal 10670, dated, March 12, 2021 to update the effective date from date of service to receipt date. All other information remains the same.

SUBJECT: Modification to Existing Common Working File (CWF) Edits for Osteoporosis Drug Codes Billable on Home Health Claims

EFFECTIVE DATE: January 1, 2021 - For claims received on or after this date

\*Unless otherwise specified, the effective date is the date of service.

**IMPLEMENTATION DATE: July 6, 2021** 

### I. GENERAL INFORMATION

A. Background: Sections 1861(m) and 1861(kk) of the Social Security Act provide for coverage of Food and Drug Administration (FDA) approved injectable drugs for osteoporosis provided by a Home Health Agency (HHA) to female beneficiaries who meet certain criteria. Initially, the only FDA approved injectable drug for osteoporosis was calcitonin. Effective for dates of services on or after January 1, 2005, Medicare also began covering teriparatide (brand named Forteo), an injectable drug approved by the FDA for use in treating osteoporosis. Since that time, there have been additional drugs approved for use in treating osteoporosis that would be covered under the Medicare home health benefit if provided by a HHA to eligible female beneficiaries. These include osteoporosis drugs that have the ingredient denosumab (brand names Xgeva and Prolia), romosozumab-aqqg (brand name Evenity) or abaloparatide (brand name, Tymlos).

Like the calcitonin based osteoporosis drug and teriparatide, denosumab, romosozumab-aqqg, and abaloparatideare paid on a cost basis and are subject to deductible and coinsurance. Denosumab may be billed using Healthcare Common Procedure Coding System (HCPCS) code J0897. Romosozumab-aqqg may be billed using HCPCS code J3111. Abaloparatide may be billed using HCPCS code J3590.

These three new HCPCS codes were implemented by Change Request (CR) 11846, for claims with dates of service on and after January 01, 2021. The CMS has determined that two edits need modification to reflect these new HCPCS codes. This CR instructs CWF to make the modifications.

**B. Policy:** This CR contains no policy changes.

## II. BUSINESS REQUIREMENTS TABLE

"Shall" denotes a mandatory requirement, and "should" denotes an optional requirement.

Number	Requirement	Responsibility								
			A/B		D	Shared-		-	Other	
		N	MA(	AC M			Sys	tem	l	
			I		Е	Maintainers			ers	
		Α	В	Н		F	M	V	C	
				Н	M	I	C	M	W	
				Н	A	S	S	S	F	
					C	S				
12016.1	The contractor shall add HCPCS codes J0897, J3111								X	
	and J3590 to the edit requiring that the Provider									

Number	Requirement	Responsibility								
		A/B MAC		A/B			Sys	red- tem aine		Other
		A	В	H H H		F	M	V	C W F	
	Number is the same as on the Home Health Prospective Payment System (PPS) episode if the claim contains:  1. Type of Bill (TOB) '34x' with Revenue Code '0636' and 2. Osteoporosis drug HCPCS codes.									
12016.2	The contractor shall add HCPCS codes J0897, J3111 and J3590 to the edit preventing duplicate payment of osteoporosis services if the claim contains:  1. TOB '034x' with osteoporosis drug HCPCS codes and 2. In history is an outpatient claim with TOB '034x' and any osteoporosis drug HCPCS codes for the same date of service.								X	

# III. PROVIDER EDUCATION TABLE

Number	Requirement	Re	Responsibility			
			A/B		D	C
		MAC			M	Е
					Е	D
		Α	В	Н		I
				Н	M	
				Н	Α	
					C	
	None					

# IV. SUPPORTING INFORMATION

# Section A: Recommendations and supporting information associated with listed requirements:

<sup>&</sup>quot;Should" denotes a recommendation.

X-Ref	Recommendations or other supporting information:
Requirement	
Number	
.1 and .2	These BRs change the existing CWF edits.'5384' and '7283'

## Section B: All other recommendations and supporting information: N/A

### V. CONTACTS

**Pre-Implementation Contact(s):** Wil Gehne, wilfried.gehne@cms.hhs.gov , Kajol Balani, kajol.balani@cms.hhs.gov

**Post-Implementation Contact(s):** Contact your Contracting Officer's Representative (COR).

### VI. FUNDING

### **Section A: For Medicare Administrative Contractors (MACs):**

The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer. If the contractor considers anything provided, as described above, to be outside the current scope of work, the contractor shall withhold performance on the part(s) in question and immediately notify the Contracting Officer, in writing or by e-mail, and request formal directions regarding continued performance requirements.

**ATTACHMENTS: 0**